Download PDF
Klin Monbl Augenheilkd 2018; 235(02): 151-156
DOI: 10.1055/s-0044-101260
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Risikofaktoren und Zielwerte in der kardiovaskulären Primär- und Sekundärprävention: Bedeutung für das Glaukom

Risk Factors and Therapeutic Goals for Primary and Secondary Cardiovascular Prevention: Significance for the Glaucoma Patient
Claudia Hacke
1   Institut für Medizinische Biometrie und Epidemiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
,
Carl Erb
2   Augenklinik am Wittenbergplatz, Berlin
,
Burkhard Weisser
3   Institut für Sportwissenschaft, Sportmedizin, Christian-Albrechts-Universität, Kiel
› Author Affiliations
Further Information

Publication History

eingereicht 18 December 2017

akzeptiert 17 January 2018

Publication Date:
15 February 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bluthochdruck, Diabetes mellitus und Fettstoffwechselstörungen gehören zu den wichtigsten kardiovaskulären Risikofaktoren. Gleichzeitig besteht auch ein Zusammenhang mit der Entwicklung und Progression des Glaukoms. In den letzten Jahren wurde eine intensive Diskussion über die optimalen Zielwerte für diese Risikofaktoren geführt. Vor kurzer Zeit haben die amerikanischen Fachgesellschaften 130/80 mmHg als neue Grenze zum Bluthochdruck definiert und auch europäische Richtlinien werden folgen. Die strengeren Grenzwerte erhöhen die Gefahr, dass unter Umständen ein zu starker Blutdruckabfall in der Nacht beim Glaukompatienten erfolgen könnte. Im Gegensatz dazu sollte das LDL-Cholesterin so niedrig wie möglich eingestellt werden („the lower the better“). Differenzierter sind die Zielbereiche beim Diabetes mellitus zu sehen. Für Ältere, also die Hauptgruppe der Glaukompatienten, wird inzwischen eine eher moderate Blutzuckereinstellung mit einem HbA1c-Wert von über 7% empfohlen, um stärkere Unterzuckerungen zu vermeiden. In der vorliegenden Zusammenfassung werden die Bedeutung kardiovaskulärer Risikofaktoren und deren therapeutische Zielbereiche für die Ophthalmologie bei der Therapie von Glaukompatienten dargestellt.

Abstract

Hypertension, diabetes mellitus and dyslipidaemia are among the most important cardiovascular risk factors. In addition, there is an association with the development and progression of glaucoma. During the last years, there has been an intense discussion concerning optimal treatment goals for these risk factors. Recently, the American Heart Association has defined a blood pressure greater than 130/80 mmHg as hypertension and the European guidelines will follow this definition. These lower blood pressure limits increase the risk for a too strict blood pressure treatment with night values, which might be too low for glaucoma patients. In contrast, the treatment goals for LDL cholesterol should be as low as possible (“the lower the better”). There is a more differentiated picture concerning treatment goals for diabetes mellitus. For elderly patients, which is the main group of the glaucoma patients, a less intense blood sugar reduction is currently recommended with an HbA1c value of above 7%. The present paper summarizes the significance of cardiovascular risk factors and the respective treatment goals for the therapy of patients with glaucoma.

Schlüsselwörter

Hypertonie - Diabetes mellitus - Fettstoffwechselstörungen - Glaukom

Key words

hypertension - diabetes mellitus - dyslipidaemia - glaucoma
 

  • Literatur

  • 1 Chen YY, Hu HY, Chu D. et al. Patients with primary open-angle glaucoma may develop ischemic heart disease more often than those without glaucoma: an 11-year population-based cohort study. PLoS One 2016; 11: e0163210
    CrossrefPubMedGoogle Scholar
  • 2 Erb C, Weisser B. The importance of systemic hypertension for eye diseases. Dtsch Med Wochenschr 2004; 129: 2486-2490
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1593-1601
    CrossrefPubMedGoogle Scholar
  • 4 Lin HC, Chien CW, Hu CC. et al. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. Ophthalmology 2010; 117: 2088-2095
    CrossrefPubMedGoogle Scholar
  • 5 Graham S, Drance S. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999; 43 (Suppl. 01) S10-S16
    CrossrefPubMedGoogle Scholar
  • 6 Hayreh S, Zimmerman M, Podhajsky P. et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117: 603-624
    CrossrefPubMedGoogle Scholar
  • 7 Charlson ME, de Moraes CG, Link A. et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology 2014; 121: 2004-2012
    CrossrefPubMedGoogle Scholar
  • 8 Collignon N, Dewe W, Guillaume S. et al. Ambulatory blood pressure monitoring in glaucoma patients. The nocturnal systolic dip and its relationship with disease progression. Int Ophthalmol 1998; 22: 19-25
    CrossrefPubMedGoogle Scholar
  • 9 Krasińska B, Karolczak-Kulesza M, Krasiński Z. et al. A marked fall in nocturnal blood pressure is associated with the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2011; 20: 171-181
    CrossrefPubMedGoogle Scholar
  • 10 Pache M, Dubler B, Flammer J. Peripheral vasospasm and nocturnal blood pressure dipping – two distinct risk factors for glaucomatous damage?. Eur J Ophthalmol 2003; 13: 260-265
    CrossrefPubMedGoogle Scholar
  • 11 Perlman J, Delany C, Sothern R. et al. Relationships between 24 h observations in intraocular pressure vs. blood pressure, heart rate, nitric oxide and age in the medical chronobiology aging project. Clin Ter 2007; 158: 31-47
    PubMedGoogle Scholar
  • 12 Parati G, Stergiou G, OʼBrien E. et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32: 1359-1366
    CrossrefPubMedGoogle Scholar
  • 13 Plange N, Kaup M, Daneljan L. et al. 24-h blood pressure monitoring in normal tension glaucoma: night-time blood pressure variability. J Hum Hypertens 2006; 20: 137-142
    CrossrefPubMedGoogle Scholar
  • 14 Kochkorov A, Gugleta K, Katamay R. et al. Short-term variability of systemic blood pressure and submacular choroidal blood flow in eyes of patients with primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2010; 248: 833-837
    CrossrefPubMedGoogle Scholar
  • 15 Wierzbowska J, Wierzbowski R, Stankiewicz A. et al. Cardiac autonomic dysfunction in patients with normal tension glaucoma: 24-h heart rate and blood pressure variability analysis. Br J Ophthalmol 2012; 96: 624-628
    CrossrefPubMedGoogle Scholar
  • 16 Bowe A, Grünig M, Schubert J. et al. Circadian variation in arterial blood pressure and glaucomatous optic neuropathy – a systematic review and meta-analysis. Am J Hypertens 2015; 28: 1077-1082
    CrossrefPubMedGoogle Scholar
  • 17 Tokunaga T, Kashiwagi K, Tsumura T. et al. Association between nocturnal blood pressure reduction and progression of visual field defect in patients with primary open-angle glaucoma or normal-tension glaucoma. Jpn J Ophthalmol 2004; 48: 380-385
    CrossrefPubMedGoogle Scholar
  • 18 Erb C, Predel H. Die Bedeutung der arteriellen Hypertonie für das primäre Offenwinkelglaukom. Klin Monatsbl Augenheilkd 2014; 231: 136-143
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Weisser B, Erb C. Ambulatory 24-h blood pressure measurement in patients with glaucoma. Klin Monatsbl Augenheilkd 2015; 232: 169-173
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Nesher R, Kohen R, Shulman S. et al. Diastolic double-product: a new entity to consider in normal-tension glaucoma patients. Isr Med Assoc J 2012; 14: 240-243
    PubMedGoogle Scholar
  • 21 Whelton PK, Carey RM, Aronow WS. et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017; DOI: 10.1161/HYP.0000000000000065.
    PubMedGoogle Scholar
  • 22 SPRINT Research Group, Wright JT jr., Williamson JD, Whelton PK et al. A randomized trial of intensive versus standard blood-pressure Control. N Engl J Med 2015; 373: 2103-2116
    CrossrefPubMedGoogle Scholar
  • 23 Krämer BK, Hausberg M, Sanner B. et al. Blutdruckmessung und Zielblutdruck – Stellungnahme der Deutschen Hochdruckliga e.V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention. Dtsch Med Wochenschr 2017; 142: 1446-1447
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Krasińska B, Karolczak-Kulesza M, Krasiński Z. et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2012; 21: 240-248
    CrossrefPubMedGoogle Scholar
  • 25 Jünemann AG, Huchzermeyer C, Rejdak R. et al. Dyslipidaemia and glaucoma. Klin Monatsbl Augenheilkd 2014; 231: 1203-1214
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Helin-Toiviainen M, Rönkkö S, Kaarniranta K. et al. Oxidized low-density lipoprotein, lipid and calcium aggregates reveal oxidative stress and inflammation in the conjunctiva of glaucoma patients. Acta Ophthalmol 2017; 95: 378-385
    CrossrefPubMedGoogle Scholar
  • 27 Benoist dʼAzy C, Pereira B, Chiambaretta F. et al. Oxidative and anti-oxidative stress markers in chronic glaucoma: a systematic review and meta-analysis. PLoS One 2016; 11: e0166915
    CrossrefPubMedGoogle Scholar
  • 28 Wang S, Xu L, Jonas JB. et al. Dyslipidemia and eye diseases in the adult Chinese population: the Beijing eye study. PLoS One 2012; 7: e26871 doi:10.1371/journal.pone.0026871
    CrossrefPubMedGoogle Scholar
  • 29 Shoji T, Sakurai Y, Sato H. et al. Serum low-density lipoprotein cholesterol level is strong risk factor for acquired color vision impairment in young to middle-aged Japanese men: the Okubo Color Study Report 2. Atherosclerosis 2010; 210: 542-547
    CrossrefPubMedGoogle Scholar
  • 30 Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999-3058
    CrossrefPubMedGoogle Scholar
  • 31 Whigham B, Oddone EZ, Woolson S. et al. The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis. Ophthalmic Epidemiol 2017; DOI: 10.1080/09286586.2017.1399427.
    PubMedGoogle Scholar
  • 32 McCann P, Hogg RE, Fallis R. et al. The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2016; 57: 2729-2748
    CrossrefPubMedGoogle Scholar
  • 33 Stein JD, Newman-Casey PA, Talwar N. et al. The relationship between statin use and open-angle glaucoma. Ophthalmology 2012; 119: 2074-2081
    CrossrefPubMedGoogle Scholar
  • 34 De Castro DK, Punjabi OS, Bostrom AG. et al. Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Exp Ophthalmol 2007; 35: 506-513
    CrossrefPubMedGoogle Scholar
  • 35 Song BJ, Aiello LP, Pasquale LR. Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep 2016; 16: 124
    CrossrefPubMedGoogle Scholar
  • 36 Zhou M, Wang W, Huang W. et al. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLoS One 2014; 9: e102972 doi:10.1371/journal.pone.0102972
    Google Scholar
  • 37 Gerber AL, Harris A, Siesky B. et al. Vascular dysfunction in diabetes and glaucoma: a complex relationship reviewed. J Glaucoma 2015; 24: 474-479
    CrossrefPubMedGoogle Scholar
  • 38 Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7: 369-375
    CrossrefPubMedGoogle Scholar
  • 39 Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Diabetologie 2016; 11 (Suppl. 02) S170-S176
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Landgraf R, Kellerer M, Fach E. Praxisempfehlungen DDG/DGIM Therapie des Typ-2-Diabetes. Diabetologie 2013; 8 (Suppl. 02) S146-S158
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Pelletier AL, Rojas-Roldan L, Coffin J. Vision loss in older adults. Am Fam Physician 2016; 94: 219-226
    PubMedGoogle Scholar